Stronger Warning for Asthma Drug Xolair
February 2007
If you, or someone you care about, take Xolair it may cause shortness of breath instead of relieving your asthma symptoms. Because of continued adverse side effects, the Food and Drug Administration (FDA) has proposed that the manufacturer, Genetech, Inc., modify the package of Xolair with a boxed warning.
Xolair is specifically designed to aid allergy sufferers who have not experienced adequate relief from asthma using more traditional steroid-based medications. However, Xolair has been linked to cases of anaphylaxis in approximately one out of every 1,000 users of the product. Anaphylaxis causes shortness of breath, tightening in the chest, dizziness, fainting, hives, and itching. Any dose of Xolair could lead to anaphylaxis in patients, even if the first dose of the drug caused no adverse reaction. Signs of anaphylaxis in users may not surface until up to 24 hours after using Xolair.
Have You Suffered Injuries Due to Xolair? Contact Us Now For a Free Evaluation of Your Legal Case.
Call us toll-free at 1-866-943-3427 or get online legal help, and we'll give you a free evaluation of your claim.
Please note: All of our lawyers are licensed to practice in the state of Pennsylvania. We also have lawyers licensed to practice in Ohio and West Virginia, and we associate with experienced attorneys in other states. In addition, all drug-related litigation involves co-counsel.
Source: "FDA Proposes to Strengthen Label Warning for Xolair." FDA Press Release. February 21, 2007.



